Measurement of problem behaviour during medication evaluations

Journal of Intellectual Disability Research

Volumn 52, Issue 12, 2008, Pages 1015-1028

  Zarcone, Jennifer R ^a   Napolitano, D ^a   Valdovinos, M ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DRAKE UNIVERSITY   (United States)

Author keywords

Function alanalysis; Psychotropic medication; Side effects

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD BEHAVIOR CHECKLIST; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMUNICATION SKILL; CONDUCT DISORDER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HUMAN; INTELLECTUAL IMPAIRMENT; MEDICAL RECORD; OBSERVATIONAL STUDY; PSYCHOPHARMACOTHERAPY; RATING SCALE; REVIEW; SIDE EFFECT; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PSYCHOTROPIC DRUGS; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 56649111015     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2008.01109.x     Document Type: Review

References (119)

1. Achenbach T. M. & Rescorla L. A. (2001) Manual for ASEBA School-Age Forms and Profiles. University of Vermont, Research Center for Children, Youth, and Families. Burlington, VT.
2. Achenbach T. M., McConaughy S. H. & Howell C. T. (1987) Child/ adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin 101, 213-32.
3. Advokat C. D., Mayville E. A. & Matson J. L. (2000) Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities 21, 75-84.
4. Alvarez-Requejo A., Carvajal A., Begaud B., Moride Y., Vega T. & Martin Arias L. H. (1998) Under-reporting of adverse drug reactions: estimate based upon spontaneous reporting scheme and a sentinel system. European Journal of Clinical Pharmacology 54, 483-8.
5. Aman M. G. & Singh N. N. (1988) Psychopharmacology of the Developmental Disabilities. Springer-Verlag, Berlin.
6. Aman M. G. & Wolford P. L. (1995) Consumer satisfaction with involvement in drug research: A social validity study. Journal of American Academy of Child and Adolescent Psychiatry 34, 940-945.
7. Aman M. G., Singh N. N., Stewart A. W. & Field C. J. (1985) The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 89, 485-91.
8. Aman M. G., Singh N. N. & White A. J. (1987) Caregiver perceptions of psychotropic medication in residential facilities. Research in Developmental Disabilities 8, 449-65.
9. Aman M. G., Burrow W. H. & Wolford P. L. (1995) The Aberrant Behavior Checklist - community. Factor validity and the effect of subject variables for adults in group homes. American Journal on Mental Retardation 100, 283-92.
10. Aman M. G., TasséM. J., Rojahn J. & Hammer D. (1996) The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities 17, 41-57.
11. Aman M. G., Alvarez N., Benefield W., Crismon M., Green G., King B. et al. (2000) Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation 105, 159-228.
12. Aman M. G., Novotny S., Samango-Sprouse C., Lecavalier L., Leonard W., Gadow K. et al. (2004) Outcome measures for clinical drug trials in autism. CNS Spectrums 9, 36-47.
13. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and the Committee on Qualify Improvement (2001) Clinical practice guidelines: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108, 1033-44.
14. Anderson G. M., Zimmerman A. W., Akshoomoff N. & Chugani D. C. (2004) Autism clinical trials: Biological and medical issues in patient selection and treatment response. CNS Spectrums 9, 57-64.
15. Argus G. R., Terry P. C., Bramston P. & Dinsdale S. L. (2004) Measurement of mood in adolescents with intellectual disability. Research in Developmental Disability 25, 493-507.
16. Arscott K., Kroese B. S. & Dagnan D. (2000) A study of the knowledge that people with intellectual disabilities have of their prescribed medication. Journal of Applied Research in Intellectual Disabilities 13, 90-9.
17. Basile V. S., Masellis M., McIntyre R. S., Meltzer H. Y., Lieberman J. A. & Kennedy J. L. (2001) Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry 62, 45-66.
18. Baumeister A. A. & Sevin J. A. (1990) Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach. Neuroscience and Biobehavioral Reviews 14, 253-62.
19. Bech P. (1981) Rating scales for affective disorders: Their validity and consistency. Acta Psychiatrica Scandinavica S295, 11-93.
20. Benton D. (2007) The impact of diet on anti-social, violent and criminal behaviour. Neuroscience and Biobehavioral Reviews 31, 752-74.
21. Biederman J., Mick. E., Faraone S. V., Wozniak J., Spencer T. & Pandina G. (2006) Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapy 28, 794-800.
22. Blough D., Pulliam B., Page T. J., Sweeney V., Dougherty R. & Grim M. (2006) Improving evaluation of psychotropic medication for adults with developmental disabilities living in community settings. Behavioral Interventions 21, 73-83.
23. Bodfish J. W., Symons F. J. & Lewis M. H. (1999) The Repetitive Behavior Scales. Western Carolina Center Research Reports, Morgantown, NC.
24. Bork J. A., Rogers T., Wedlund P. J. & de Leon J. (1999) A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A. Journal of Clinical Psychiatry 61, 600-1.
25. Borthwick-Duffy S. A. (1994) Epidemiology and prevalence of psychopathology in people with mental retardation. Journal of Consulting and Clinical Psychology 62, 17-27.
26. Bradley E. A., Summers J., Brereton A. V., Einfeld S. L., Havercamp S. M., Holt G. etal. (2007) Intellectual disabilities and behavioral, emotional, and psychiatric disturbances. In: A Comprehensive Guide to Intellectual and Developmental Disabilities (eds. I. Brown & M. Percy), pp. 645-6. Paul H. Brookes. Baltimore, MD.
27. Bukstein O. G. (2004) Satisfaction with treatment for attention-deficit/ hyperactivity disorder. American Journal of Managed Care 10, S107-S116.
28. Campbell M. & Palij M. (1985) Measurement of side effects including tardive dyskinesia. Psychopharmacology Bulletin 21, 1063-80.
29. Chacko A., Pelham W. E., Gnagy E. M., Greiner A., Vallano G., Bukstein O. et al. (2005) Stimulant medication effects in a summer treatment program among young children with attention-deficit/Hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 44, 249-57.
30. Cheymol G. (2000) Effects of obesity on pharmacokinetics: Implications for drug therapy. Clinical Pharmacokinetics 39, 215-31.
31. Christian L., Snycerski S. M., Singh N. N. & Poling A. (1999) Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability. Journal of Intellectual Disability Research 43, 88-93.
32. Cicchetti D. V. & Prusoff B. A. (1983) Reliability of depression and associated clinical symptoms. Archives of General Psychiatry 40, 987-90.
33. Cooper J. O., Heron T. E. & Heward W. L. (2007) Applied Behavior Analysis. Pearson/Merrill - Prentice Hall, Upper Saddle River, NJ.
34. Correll C. U. & Malhotra A. K. (2004) Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berlin) 174, 477-89.
35. Corso D. M., Pucino F., DeLeo J. M., Calis K. A. & Gallelli J. F. (1992) Development of a questionnaire for detecting potential adverse drug reactions. The Annals of Pharmacotherapy 26, 890-6.
36. Cotter P. E. & O'Keeffe S. T. (2007) Improvement in neuroleptic-induced akathisia with intravenous iron treatment in a patient with iron deficiency. Journal of Neurology, Neurosurgery, and Psychiatry 78, 548.
37. Cuthill F. M., Espie C. A. & Cooper S. (2003) Development and psychometric properties of the Glasgow Depression Scale for people with a Learning Disability: Individual and carer supplement versions. The British Journal of Psychiatry 182, 347-53.
38. Dahl M. L. (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clinical Pharmocokinetics 41, 453-70.
39. DesNoyers Hurley A., Reiss S., Aman M. G., Salvador-Carulla L., Demb H., Loschen E. et al. (1998) Instruments for assessing effects of pscychotropic medication. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook (eds S. Reiss & M. G. Aman), pp. 85-94. The Ohio State University Nisonger Center. Columbia, OH.
40. Dicesare A., McAdam D. B., Toner A. & Varrell J. (2005) The effects of methylphenidate on a functional analysis of disruptive behavior: A replication and extension. Journal of Applied Behavior Analysis 38, 125-8.
41. Dormann H., Muth-Selbach U., Krebs S., Criegee-Rieck M., Tegeder I., Schneider H. T. et al. (2000) Incidence and costs of adverse drug reactions during hospitalization. Drug Safety 22, 161-8.
42. Einfeld S. L. & Tonge B. J. (1995) The developmental behaviour checklist: The development and validation of an instrument to assess behavioural and emotional disturbance in children and adolescents with mental retardation. Journal of Autism and Developmental Disorders 25, 81-104.
43. Epstein M. H., Singh N. N., Luebke J. & Stout C. E. (1991) Psychopharmacological intervention. II: Teacher perceptions of psychotropic medication for students with learning disabilities. Journal of Learning Disabilities 24, 477-83.
44. Findling R. L., Reed M. D., O'Riordan M. A., Demeter C. A., Stansbrey R. J. & McNamara N. K. (2006) Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry 45, 792-800.
45. Findling R. L., Reed M. D., O'Riordan M. A., Demeter C. A., Stansbrey R. J. & McNamara N. K. (2007) A 26-week open-label study of quetiapine in children with conduct disorder. Journal of Child and Adolescent Psychopharmacology 17, 1-9.
46. Finlay W. M. L. & Lyons E. (2001) Methodological issues in interviewing and using self-report questionnaires with people with mental retardation. Psychological Assessment 13, 319-35.
47. Foy J. M. & Earls M. F. (2005) A process for developing community consensus regarding the diagnosis and management of attention-deficit/ hyperactivity disorder. Pediatrics 115, 97-104.
48. Freeman B. J., Ritvo E. R., Yokata A. & Ritvo A. (1986) A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American Academy of Child and Adolescent Psychiatry 25, 130-6.
49. Freund L. S. & Reiss A. L. (1991) Rating problem behaviors in outpatients with mental retardation: Use of the Aberrant Behavior Checklist. Research in Developmental Disabilities 12, 435-51.
50. Gedye A. (1992) Recognizing obsessive-compulsive disorder in clients with developmental disabilities. Habilitative Mental Healthcare Newsletter II, 73-7.
51. Gérardin P., Cohen D., Mazet P. & Flament M. F. (2002) Drug treatment of conduct disorder in young people. European Neuropsychopharmacology 12, 361-70.
52. Goodman W. K., Price L. H., Rasmussen S. A., Mazure C., Delgado P., Heninger G. R. et al. (1989a) The Yale-Brown Obsessive Compulsive Scale: II. Validity. Archives of General Psychiatry 46, 1012-16.
53. Goodman W. K., Price L. H., Rasmussen S. A., Mazure C., Fleischmann R. L., Hill C. L. et al. (1989b) The Yale-Brown Obsessive-Compulsive Scale: I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-11.
54. Guy W. (1976) Assessment Manual for Psychopharmacology. U.S. Government Printing Office, Washington, DC.
55. Hale J. B., Hoeppner J. A., DeWitt M. B., Coury D. L., Ritacco D. G. & Trommer B. (1998) Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology. Journal of Learning Disabilities 31, 595-607.
56. Hellings J. A., Weckbaugh M., Nickel E., Cain S. E., Zarcone J. R., Reese R. M. et al. (2005) A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 15, 682-92.
57. Hollander E. & Anagnostou E. (2007) Clinical Manual for the Treatment of Autism. American Psychiatric Publishers, Inc., Arlington, VA.
58. Hollander E., Phillips A., King B. H., Gutherie D., Aman M. G., Law P. et al. (2004) Impact of recent findings on study design of future autism clinical trials. CNS Spectrum 9, 49-56.
59. Iwata B. A., Dorsey M., Slifer K., Bauman K. & Richman G. (1994) Toward a functional analysis of self-injury. Journal of Applied Behavior Analysis 27, 197-209.
60. Johnson C. R., Handen B. L., Lubetsky M. J. & Sacco K. A. (1994) Efficacy of methylphenidate and behavioral intervention on classroom behavior in children with ADHD and mental retardation. Behavior Modification 18, 470-87.
61. Kalachnik J. E. (1988) Medication monitoring procedures: Thou shall, here's how. In: Pharmacotherapy and Mental Retardation (eds K. D. Gadow & A. D. Poling), pp. 231-268. College-Hill, Boston, MA.
62. Kalachnik J. E. (1999) Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews 5, 348-59.
63. Kalachnik J. E. & Sprague R. L. (1993) The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. Journal of Clinical Psychology 49, 177-89.
64. Kayser K. H., Wacker D. P., Derby K. M., Andelman M. S., Golonka Z. & Stoner E. (1997) A rapid method for evaluating the necessity for both a behavioral intervention and methylphenidate. Journal of Applied Behavior Analysis 30, 177-80.
65. Kemph J. P., DeVane C. L., Levin G. M., Jarecke R., Miller R. L. (1993) Treatment of aggressive children with clonidine: Results of an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 32, 577-81.
66. Kronenberg W. G., Giauque A. L., Lafata D. E., Bohnstedt B. N., Maxey L. E. & Dunn D. N. (2007) Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/ oppositional-defiant disorder, and aggression: A prospective, open-label study. Journal of Child and Adolescent Psychopharmacology 17, 334-47.
67. Kuloglu M., Atmaca M., Üstündag B., Canatan H., Gecici O. & Tezcan E. (2003) Serum iron levels in schizophrenic patients with or without akathisia. European Neuropsychopharmacology 13, 67-71.
68. de Leon J., Armstrong S. & Cozza, K. L. (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47, 75-85.
69. McAdam D. B., Zarcone J. R., Hellings J., Napolitano D. A. & Schroeder S. R. (2002) Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. American Journal on Mental Retardation 107, 261-9.
70. McDougle C. J., Holmes J. P., Bronson M. R., Anderson G. M., Volkmar F. R., Price L. H. et al. (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of American Academy of Child and Adolescent Psychiatry 36, 685-93.
71. McDougle C. J., Holmes J. P., Carlson D. C., Pelton G. H., Cohen D. J. & Price L. H. (1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry 55, 633-41.
72. Marshburn E. C. & Aman M. G. (1992) Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders 22, 357-73.
73. Matson J. L. (1995) Manual for the Diagnostic Assessment for the Severely Handicapped-II. Louisiana State University Press, Baton Rouge, LA.
74. Matson J. L., Barett R. P. & Helsel W. J. (1988) Depression in mentally retarded children. Research in Developmental Disabilities 9, 39-46.
75. Matson J. L., Mayville E. A., Bielecki J., Barnes W. H., Bamburg J. W. & Baglio C. S. (1998) Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS). Research in Developmental Disabilities 19, 501-6.
76. Matson J. L., Bamburg J. W., Mayville E. A., Pinkston J., Bielecki J., Kuhn D. et al. (2000) Psychopharmacology and mental retardation: A 10 year review (1990-1999). Research in Developmental Disabilities 21, 263-96.
77. Matson J. L., Bielecki J., Mayville E. A. & Matson M. L. (2003) Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions. Research in Developmental Disabilities 24, 149-57.
78. Meins W. (1996) A new depression scale designed for use with adults with mental retardation. Journal of Intellectual Disability Research 40, 222-6.
79. Miral S., Gencer O., INal-Emiroglu F., Baykara B., Baykara A. & Dirik E. (2008) Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry 17, 1-8.
80. Moss S. C., Patel P., Prosser H., Goldberg D., Sinipson N., Rowe S. et al. (1993) Psychiatric morbidity in older people with moderate and severe learning disability (mental retardation). Part I: Development and reliability of the patient interview (PAS-ADD). British Journal of Psychiatry 163, 471-80.
81. Napolitano D. A., Jack S. L., Sheldon J. B., Williams D. C., McAdam D. B. & Schroeder S. R. (1999) Drug-behavior interactions in persons with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research and Reviews 5, 322-44.
82. National Institute of Mental Health (1985) AIMS (Abnormal Involuntary Movement Scale). Psychopharmacology Bulletin 21, 1077-9.
83. Northup J., Fusilier I., Swanson V., Roane H. & Borrero J. (1997a) An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers. Journal of Applied Behavior Analysis 30, 614-26.
84. Northup J., Jones K., Broussard C., DiGiovanni G., Herring M., Fusilier I. et al. (1997b) A preliminary analysis of interactive effects between common classroom contingencies and MPH. Journal of Applied Behavior Analysis 30, 121-5.
85. Northup J., Fusilier I., Swanson V., Huete J., Bruce T., Freeland J. et al. (1999) Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies. Journal of Applied Behavior Analysis 32, 35-50.
86. Pelham W., Carlson C., Sams S., Vallano G., Dixon M. & Hoza B. (1993) Separate and combined effects of methylphenidate and behavior modification in boys with attention deficit-hyperactivity disorder in classrooms. Journal of Consulting and Clinical Psychology 61, 506-15.
87. Poling A. & LeSage M. (1995) Evaluating psychotropic drugs in people with mental retardation: Where are the social validity data? American Journal on Mental Retardation 100, 193-200.
88. Pyles D. A. M., Muniz K., Cade A. & Silva R. (1997) A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities 18, 185-214.
89. Rabkin J. G., Markowitz J. S., Ocepek-Welikson K. & Wager S. S. (1992) General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. Journal of Clinical Psychopharmacology 12, 3-10.
90. Rapport M. D., DuPaul G. J., Stoner G. & Jones J. T. (1986) Comparing classroom and clinic measures of attention deficit disorder: differential, idiosyncratic, and dose-response effects of methylphenidate. Journal of Consulting and Clinical Psychology 54, 334-41.
91. Rasaratnam R., Crouch K. & Regan A. (2004) Attitude to medication of parents/primary carers of people with intellectual disability. Journal of Intellectual Disability Research 48, 754-63.
92. Reiss S. (1997) Comments on the reiss screen for maladaptive behavior and its factor structure. Journal of Intellectual Disability Research 41, 346-54.
93. Reiss S. & Aman M. G. (1998) Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. The Ohio State University, Columbus, OH.
94. Reyes M., Croonenberghs J., Augustyns I. & Eerdekens M. (2006) Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. Journal of Child and Adolescent Psychopharmacology 16, 260-72.
95. Rojahn J. & Helsel W. J. (1991) The Aberrant Behavior Checklist with children and adolescents with dual diagnosis. Journal of Autism and Developmental Disorders 21, 17-28.
96. Rojahn J., Matson J. L., Lott D., Esbensen A. J. & Smalls Y. (2001) The behavior problems inventory: An instrument for the assessment of self-injury, stereotyped behavior and aggression/destruction in individuals with developmental disabilities. Journal of Autism and Developmental Disorders 31, 577-88.
97. Schaal D. W. & Hackenberg T. (1994) Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation 99, 123-40.
98. Schroeder S. R., Rojahn J. & Reese R. M. (1997) Brief report: reliability and validity of instruments for assessing psychotropic medication effects on self-injurious behavior in mental retardation. Journal of Autism and Developmental Disorders 27, 89-102.
99. Shariatpanaahi M. V., Shariatpanaahi Z. V., Moshtaaghi M., Shahbaazi S. H. & Abadi A. (2007) The relationship between depression and serum ferritin level. European Journal of Clinical Nutrition 61, 532-5.
100. Spina E. & Caputi A. P. (1992) Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacology Research 29, 121-37.
101. Sprague R. L. & Werry J. S. (1971) Methodology of psychopharmacological studies with the retarded. In: International Review of Research in Mental Retardation, vol. 5 (ed. N. R. Ellis), pp. 147-219. Academic Press, New York.
102. Sprague R. L., Kalachnik J. E. & Slaw K. M. (1989) Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS). Mental Retardation 27, 141-8.
103. Thompson T. & Lubinski D. (1986) Units of analysis and kinetic structure of behavioral repertoires. Journal of Experimental Analysis of Behavior 46, 219-42.
104. Thompson T., Hackenberg T., Cerutti D., Baker D. & Axtell S. (1994) Opiod antagonist effects on self-injury with mental retardation: response form and location as determinants of medication effects. American Journal of Mental Retardation 99, 85-102.
105. Thompson T., Zarcone J. & Symons F. (2004) Methodological issues in psychopharmacology for individuals with intellectual and developmental disabilities. In: International Handbook of Applied Research in Intellectual Disabilities (eds E. Emerson, C. Hatton, T. Parmeter & T. Thompson), pp. 549-80. John Wiley & Sons Limited, Chichester.
106. Thornton J. (1988) Adverse drug reaction reporting. Hospital Pharmacy 23, 489-91.
107. Tierney E., Aman M., Stout D., Pappas K., Arnold L. E., Vitiello B. et al. (2007) Parent satisfaction in a multi-site acute trial of risperidone in children with autism: A social validity study. Psychopharmacology 191, 149-57.
108. Unwin G. L. & Deb S. (2008) Use of medication for the management of behavior problems among adults with intellectual disabilities: A clinicians' consensus survey. American Journal on Mental Retardation 113, 19-31.
109. Valdovinos M. G. & Kennedy C. H. (2004) Behavior analytic conceptualization of psychotropic medication side effects. The Behavior Analyst 27, 231-8.
110. Valdovinos M. G. & Weyand D. (2006) Blood glucose levels and problem behavior. Research in Developmental Disabilities 27, 227-31.
111. Valdovinos M. G., Napolitano D. A., Zarcone J. R., Hellings J. A., Shores R. E., Williams D. C. et al. (2002) Multimodal assessment during a medication trial of risperidone for destructive behavior: Functional analysis, direct observations, checklists, and psychiatric impressions. Experimental and Clinical Psychopharmacology 10, 268-75.
112. Valdovinos M. G., Zarcone J. R., Hellings J. A. & Schroeder S. R. (2004) Using the Diagnostic Assessment of the Severely Handicapped - II (DASH-II) to measure the therapeutic effects of risperidone. Journal of Intellectual Disability Research 48, 53-9.
113. Volkmar F. R. (2001) Pharmacological interventions in autism: theoretical and practical issues. Journal of Clinical Child Psychology 30, 80-7.
114. Volpe R. J., Heick P. F. & Guerasko-Moore D. (2005) An agile behavioral model for monitring the effects of stimulant medicaiotn in school settings. Psychology in the Schools 42, 509-23.
115. Wasserman S., Iyendar R., Chaplin W. F., Watner D., Waldoks S. E., Anagnostuo E. et al. (2006) Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology 21, 363-7.
116. Wolf M. M. (1978) The case for subjective measurement, or how behavior analysis is finding it's heart. Journal of Applied Behavior Analysis 11, 203-14.
117. Yudofsky S. C., Silver J. M., Jackson W., Endicott J. & Williams D. (1986) The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry 143, 35-9.
118. Zarcone J. R., Rodgers T. A., Iwata B. A., Rourke D. & Dorsey M. F. (1991) Reliability analysis of the Motivation Assessment Scale: A failure to replicate. Research in Developmental Disabilities 12, 349-60.
119. Zarcone J. R., Lindauer S. E., Morse P. S., Crosland K. A., Valdovinos M. G., McKerchar T. L. et al. (2004) Effects of risperidone on destructive behavior of persons with developmental disabilities: IV. Functional analysis. American Journal on Mental Retardation 109, 310-21.